The aim of present study is to design and develop a solid oral extended release dosage form (tablet) of Niacin to deliver controlled release of drug at desired site at specific time comparable to the innovator product with better stability, high production feasibility, and excellent patient compatibility. The objective of the study is to evaluate the release pattern of the drug from fabricated extended release tablets and compare with marketed sample of the same drug Niaspan 1000mg ER tablet over a period of 24 hours. To carry out the stability for the optimized formulations.